Your browser doesn't support javascript.
loading
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.
Ventura, John D; Nkolola, Joseph P; Chandrashekar, Abishek; Borducchi, Erica N; Liu, Jinyan; Mercado, Noe B; Hope, David L; Giffin, Victoria M; McMahan, Katherine; Geleziunas, Romas; Murry, Jeffrey P; Yang, Yunling; Lewis, Mark G; Pau, Maria G; Wegmann, Frank; Schuitemaker, Hanneke; Fray, Emily J; Kumar, Mithra R; Siliciano, Janet D; Siliciano, Robert F; Robb, Merlin L; Michael, Nelson L; Barouch, Dan H.
Afiliación
  • Ventura JD; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Nkolola JP; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Chandrashekar A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Borducchi EN; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Hope DL; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Giffin VM; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • McMahan K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Geleziunas R; Gilead Sciences, Foster City, CA, 94404, USA.
  • Murry JP; Gilead Sciences, Foster City, CA, 94404, USA.
  • Yang Y; Gilead Sciences, Foster City, CA, 94404, USA.
  • Lewis MG; Bioqual, Rockville, MD, 20852, USA.
  • Pau MG; Janssen Infectious Diseases and Vaccines, 2301, Leiden, The Netherlands.
  • Wegmann F; Janssen Infectious Diseases and Vaccines, 2301, Leiden, The Netherlands.
  • Schuitemaker H; Janssen Infectious Diseases and Vaccines, 2301, Leiden, The Netherlands.
  • Fray EJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kumar MR; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Siliciano RF; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
  • Michael NL; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. dbarouch@bidmc.harvard.edu.
NPJ Vaccines ; 7(1): 53, 2022 May 18.
Article en En | MEDLINE | ID: mdl-35585080
ABSTRACT
Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without an SIV Envelope (Env) gp140 protein with alum adjuvant in combination with the TLR7 agonist vesatolimod (GS-9620) in 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA therapeutic vaccination led to robust humoral and cellular immune responses, and the Env protein boost increased antibody responses. Following discontinuation of ART, virologic control was observed in 5/12 animals in each vaccine group, compared with 0/12 animals in the sham control group. These data demonstrate therapeutic efficacy of Ad26/MVA vaccination with vesatolimod but no clear additional benefit of adding an Env protein boost. SIV-specific cellular immune responses correlated with virologic control. Our findings show partial efficacy of therapeutic vaccination following ART discontinuation in SIV-infected rhesus macaques.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos